TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06672146

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT05149872

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle relaxation
Description: Rocuronium will be used to induce partial paralysis

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle relaxation
Description: Rocuronium will be used to induce partial paralysis
Study: NCT06672146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06671457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Description: The intervention uses transcranial direct current stimulation (tDCS). The targeted brain regions are identified by conducting simultaneous fMRI-EEG data collection and sleep staging, comparing fMRI data between wakefulness and sleep states. Brain regions that show differences are calculated as potential targets for electrical stimulation. If no differentiated regions are found in a participant, specific areas are chosen based on individualized modeling results from previous experiments, targeting areas such as the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OPFC), medial prefrontal cortex (mPFC), and posterior cingulate cortex (PCC). Two regions are selected within each brain area for parameter scanning (with each stimulation lasting 10 seconds and EEG data recorded 10 seconds before and after stimulation).~In our prior studies, we observed a decrease in EEG microstate complexity during sleep, with electrical stimulation influencing this complexity reduction to some

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: In the sham stimulation group, the placement of the tDCS electrodes is identical to that of the active stimulation group. After the stimulation begins, the current gradually increases over 15 seconds. However, upon reaching the therapeutic current level, it immediately begins to decrease, lowering to 0 mA within 15 seconds and remaining at 0 mA throughout the rest of the session. During the last 15 seconds of the stimulation, there is another gradual decrease in current to 0 mA. This approach creates a similar subjective sensation to the real stimulation, making it difficult for participants to discern which type of electrical stimulation they are receiving.
Study: NCT06593106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryodevitalization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Bronchoscopy
Description: Undergo standard of care robotic bronchoscopy with biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with Biopsy
Description: Undergo standard of care robotic bronchoscopy with biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo standard of care surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Computed Tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tissue sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study: NCT05764408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traxi® Panniculus Retractor
Description: traxi® Panniculus Retractor is a disposable adhesive medical device designed for surgical patients with a BMI of at least 30kg/m2, to retract a pannus cephalad and expose the lower abdomen. The device is like a large sticker or bandage, posing no more than minimal risk to participants. The adhesive will be applied to the abdomen according to manufacturer instructions, just prior to a participant's scheduled ultrasound. Once the ultrasound exam has ended, the adhesive will be immediately removed and discarded.
Study: NCT06676670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real acupuncture
Description: Real Acupuncture Group Main acupoints: Hegu (bilateral), Taichong (bilateral), Taiyang (unilateral), shuogu (unilateral), Fengchi (unilateral); Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning Operation method: supine position, skin routine disinfection. The special model of acupuncture and moxibustion (0.30mm × 30mm), fix the gasket on the acupoint skin with seam free tape, and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept for 30 minutes. During this period, the technique of small amplitude uniform lifting, inserting and twisting (3 times) will be performed every 10 minutes. A total of four times of needling will be performed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Sham acupuncture group Acupoint selection: select eight stimulation points at the neck and shoulder. Stimulation point 1: the midpoint of the line between the shoulder well and the giant bone (both sides); Stimulation point 2: 5 inches (both sides) of the inferior paraspinal process of the seventh thoracic vertebra; Stimulus point 3: the inferior paraspinal process of the eighth thoracic vertebra will be opened 5 inches (bilateral); Stimulus point 4: 5 inches (both sides) of the infraspinous process of the ninth thoracic vertebra.~Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning to avoid acupoints.~Operation method: supine position, skin routine disinfection. Streitberger acupuncture (0. 300×30mm). Fix the gasket on the acupoint skin with seam free tape,and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept fo
Study: NCT06612424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTERİOR QUADRATUS LUMBORUM BLOCK
Description: In the Quadratus Lumborum block group, Participants will be placed in the lateral decubitus position. A convex ultrasound probe will be placed in sterile conditions along the midaxillary line, in the subcostal area above the iliac crest, to visualize the quadratus lumborum and psoas major muscles, as well as the L4 vertebral transverse process. Using an in-plane technique, a 22G, 100 mm peripheral block needle will be advanced anterior to the quadratus lumborum muscle and into the subfascial space between the quadratus lumborum and psoas major muscles. After confirming the correct location with hydrodissection, 25 mL of 0.25% bupivacaine will be injected slowly, observing the fascial displacement on ultrasound. The same procedure will be repeated on the contralateral side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: İNTRATECHAL MORPHİNE GROUP
Description: In the intrathecal morphine group, 100 micrograms of morphine (0.1 mL) will be added to the 12 mg of intrathecally administered bupivacaine.
Study: NCT06677918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP395
Description: Capsule for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule for oral use
Study: NCT06681233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison of HyperSight CBCT imaging to conventional CBCT imaging.
Description: Participants will receive their daily radiation treatment on a radiation therapy system equipped with HyperSight CBCT imaging. For at least 1 and up to 3 treatment fractions, participants will receive their daily radiation treatment on a system equipped with conventional CBCT imaging.
Study: NCT06681493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-4729 Tartrate injection
Description: Infusion, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-4729 Tartrate injection
Description: Infusion, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-4729 simulated injection
Description: Infusion, QD
Study: NCT06680167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia (heavy bupivacaine 0.5%)
Description: 12.5mg of Heavy bupivacaine 0.5% will be injected intrathecally for women undergoing elective caesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia (hyperbaric Prilocaine 2%)
Description: 60mg of Hyperbaric Prilocaine 2% will be injected intrathecally for women undergoing elective caesarean section
Study: NCT05240599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Exercise training will be applied 3 times a day for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Exercise training will be applied 3 times a day for 8 weeks.
Study: NCT05626387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil plus prednisolone
Description: Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms. Mycophenolate mofetil (MMF) is an immunosuppressive drug that acts by inhibiting the proliferation of T-lymphocytes and suppressing the recruitment of lymphocytes and monocytes into the sites of inflammation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms.
Study: NCT05240599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Exercise training will be applied 3 times a day for 8 weeks.
Study: NCT06680973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-Based Resistance Training
Description: Participants will undergo resistance training using a weight training station and elastic equipment (elastic bands and tubes).~The intensity of the resistance training with the weight training station will be determined based on 1 Repetition Maximum (1RM). Resistance training with the weight training station will be conducted at 30-70% of the 1RM intensity and will include the following exercises: leg extension, pull down, chest press, and pec deck.~The intensity of resistance training using elastic equipment will be determined according to the individual's perceived exertion. Resistance training with elastic equipment will be performed at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard) for movements involving hip flexion, extension, abduction, and adduction.~The resistance training regimen will consist of 8-12 repetitions, 2-3 sets, with at least 1 minute of rest between sets, twice a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based Resistance Training
Description: Participants will undergo resistance training at home using elastic equipment (elastic bands and tubes). The intensity of the resistance training will be determined based on the individual's perceived exertion. The training will be conducted at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard), with 8-12 repetitions, 2-3 sets, and a rest period of at least 1 minute between sets, twice a week for 12 weeks. Progression in training intensity will be achieved by increasing the weight once the perceived exertion, as measured on the Modified Borg Scale, falls below 3 (moderate) after completing 20 repetitions.~Resistance training will include exercises such as leg extension, pull down, chest press, pec deck, and movements involving hip flexion, extension, abduction, and adduction. To ensure individuals perform exercises correctly, follow-up will be conducted through online meetings every two weeks. These meetings will not be recorded.
Study: NCT06681155

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of plaque morphology, structure, and stability in non-culprit lesions
Description: Assessment of plaque morphology, structure, and stability in non-culprit lesions based on intravascular ultrasound and optical coherence tomography-near-infrared spectroscopy imaging technology.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of plaque morphology, structure, and stability in non-culprit lesions
Description: Assessment of plaque morphology, structure, and stability in non-culprit lesions based on intravascular ultrasound and optical coherence tomography-near-infrared spectroscopy imaging technology.
Study: NCT06681090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase
Description: The patients were administered topical corticosteroids in the form of a 0.1% triamcinolone acetonide preparation (Kenacort TM 0.1% Abbott). The medication was to be used 3 times every day for 4 weeks or until the lesion has healed, whichever occurs first. After applying the gel, the patients were instructed not to consume any fluids or food for at least 1 hour. In addition, a topical antifungal treatment consisting of Miconazole oral gel at a concentration of 2% should be applied once a day for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser
Description: First group (Group A) underwent PBM therapy using a 980 nm diode laser (elexxion nano dental laser with a flat top handpiece). The therapy included 8 sessions for 4 weeks, with 2 sessions conducted per week, all administered by the same operator. The energy was evenly distributed across all the mucosal lesions and the surrounding tissues within a 0.5 cm range using a spot-technique method with little overlap.
Study: NCT06680570

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Testing, Carbon Monoxide (CO) Breath Testing
Description: Pulmonary Function Testing FEV1 and FVC spirometry tests used to measure lung capacity among both smoker and non-smoker students.~Carbon Monoxide (CO) Breath Testing Measurements taken using a CO breath analyzer to assess CO levels in the smoker group.~Physical Activity Assessment (IPAQ-SF) The International Physical Activity Questionnaire Short Form (IPAQ-SF) used to evaluate physical activity levels and sedentary behavior among students.~Headache Impact Test (HIT-6) HIT-6 questionnaire used to assess the impact of headaches on daily life.
Study: NCT06680128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP560-A
Description: injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP560-A
Description: injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP560-A
Description: injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP560-A
Description: injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP560-A
Description: injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP560-B
Description: injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP560-B
Description: injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP560-B
Description: injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP560-B
Description: injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP560-B
Description: injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IXIARO
Description: injection volume of 0.5mL on V2(1day) and V5 (29day) in stage1 and stage2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMOJEV
Description: injection volume of 0.5mL on V5 (29day) in stage1 and stage2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: injection volume of 0.5mL on V2 (1day) in stage1 and stage2 (This is for IMOJEV placebo)
Study: NCT06681545

Intervention type: OTHER
Intervention: one to one interviews and or focus groups
Description: one to one interviews and or focus groups
Study: NCT05047185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucrictibant low dose
Description: Deucrictibant softgel capsules for oral use (PHVS416)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucrictibant high dose
Description: Deucrictibant softgel capsules for oral use (PHVS416)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucrictibant high dose
Description: Deucrictibant softgel capsules for oral use (PHVS416)
Study: NCT05149872

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle relaxation
Description: Rocuronium will be used to induce partial paralysis

Intervention type: OTHER
Group type: OTHER
Intervention: Reversal
Description: Sugamamdex will be used to reverse muscle relaxation
Study: NCT05047185

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules for oral use
Study: NCT06681532

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Native collagen membrane and bovine bone graft in treatment of class II furcation defects in lower molars
Description: The bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with native collagen membrane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bovine pericardium membrane and bovine bone graft in treatment of class II furcation defects in lower molars
Description: the bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with bovine pericardium membrane.
Study: NCT06706271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2000 IU of Vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2000 IU of Vitamin D
Study: NCT06707168

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital palpation
Description: Digital palpation for IOP measurement

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital palpation
Description: Digital palpation for IOP measurement

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cotton-tipped applicator (CTA)
Description: Cotton-tipped applicator (CTA) for IOP measurement

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cotton-tipped applicator (CTA)
Description: Cotton-tipped applicator (CTA) for IOP measurement
Study: NCT06710795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MaxTack™ Motorized Fixation Device
Description: All subjects enrolled will receive the MaxTack™ Motorized Fixation Device when used for fixation of prosthetic material to soft tissue in minimally invasive ventral hernia repair
Study: NCT04663061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical weight loss
Description: Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight
Study: NCT06650124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil + Prednisolone Participants will receive mycophenolate mofetil in combination.
Description: Participants in this arm will receive mycophenolate mofetil (MMF) starting at 1,000 mg/day for the first two weeks, increasing to 2,000 mg/day thereafter. This will be combined with prednisolone, beginning at 40-60 mg/day, with a tapering dose to 5-10 mg/day after 4-8 weeks, depending on the patient's response. MMF works by inhibiting inosine monophosphate dehydrogenase, which decreases lymphocyte proliferation, thereby reducing immune-mediated liver damage in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the induction phase of treatment. This intervention lasts for 24 weeks, with monitoring for biochemical remission (normalization of liver enzymes and IgG levels) and adverse events to assess the treatment's safety and efficacy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine + Prednisolone
Description: In this arm, participants will receive azathioprine (AZA) starting at 50 mg/day for the first two weeks, followed by an increase to 100 mg/day. This dose will be combined with prednisolone, starting at 40-60 mg/day, with the dosage tapering to 5-10 mg/day after 4-8 weeks, depending on patient response. Azathioprine works as an immunosuppressive agent by inhibiting DNA synthesis in rapidly dividing immune cells, thereby reducing liver inflammation in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the initial treatment phase. The intervention lasts for 24 weeks with regular monitoring for biochemical remission, defined as normalization of liver enzymes (AST, ALT) and IgG levels, as well as the occurrence of adverse events to assess safety and tolerability.